Task order: preclinical testing of CD73 inhibitors for pancreatic cancer immunoprevention
Ended Awarded Last action
- Contract number
- 75N91020F00002
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,191,330
Award facts
- Opportunity
- Contract value 100% obligated
- $1,191,330.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Houston, TX 77030, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Exercise an Option | $802,476 | |
| Original award | $388,854 |
About this award
This is a delivery order issued under the National Institutes of Health (NIH) PREVENT Preclinical Drug Development Program (PREVENT) indefinite delivery, indefinite quantity (IDIQ) contract. The award was made to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, to conduct preclinical testing of CD73 inhibitors for pancreatic cancer immunoprevention. The potential value of this task order is $1,191,330.00, with a completion date of December 20, 2023. The contract has a firm fixed price pricing type and was not set aside for any particular business category. This award supports the PREVENT program's focus on preclinical efficacy and intermediate biomarkers research, which is overseen by the National Cancer Institute (NCI), a component of the Department of Health and Human Services.
Quick answers
Who was awarded contract 75N91020F00002?
75N91020F00002 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on September 21, 2020.
How much is contract 75N91020F00002 worth?
The government has obligated $1,191,330 on 75N91020F00002.
Is contract 75N91020F00002 an order under another contract?
Yes. 75N91020F00002 is a delivery order under 75N91019D00021, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91020F00002 competed?
The extent of competition for 75N91020F00002 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award